WBI Investments LLC Invests $946,000 in Organon & Co. $OGN

Key Points

• WBI Investments LLC has invested approximately $946,000 in Organon & Co., acquiring 63,552 shares in the first quarter.
• Several institutional investors have modified their positions in Organon & Co., with BNP Paribas purchasing $2.44 million worth of shares.
• Organon & Co. recently reported earnings of $1.00 per share, outperforming the consensus estimate of $0.94, even as revenue showed a slight decline from the previous year.

WBI Investments LLC bought a new position in Organon & Co. (NYSE:OGN - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 63,552 shares of the company's stock, valued at approximately $946,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of OGN. BNP Paribas Financial Markets purchased a new position in shares of Organon & Co. in the 4th quarter worth approximately $2,443,000. Captrust Financial Advisors boosted its holdings in shares of Organon & Co. by 22.5% in the 4th quarter. Captrust Financial Advisors now owns 29,853 shares of the company's stock worth $445,000 after purchasing an additional 5,489 shares during the period. Cetera Investment Advisers boosted its holdings in shares of Organon & Co. by 62.7% in the 4th quarter. Cetera Investment Advisers now owns 76,005 shares of the company's stock worth $1,134,000 after purchasing an additional 29,287 shares during the period. Focus Partners Wealth purchased a new position in shares of Organon & Co. in the 4th quarter worth approximately $627,000. Finally, Lazard Asset Management LLC boosted its holdings in shares of Organon & Co. by 90.9% in the 4th quarter. Lazard Asset Management LLC now owns 14,509 shares of the company's stock worth $216,000 after purchasing an additional 6,909 shares during the period. Hedge funds and other institutional investors own 77.43% of the company's stock.

Wall Street Analyst Weigh In

OGN has been the subject of a number of research analyst reports. Piper Sandler decreased their price target on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. BNP Paribas raised Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $17.33.

Organon & Co. Trading Down 1.0%

Shares of NYSE OGN opened at $10.26 on Thursday. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. The business has a fifty day simple moving average of $9.61 and a two-hundred day simple moving average of $10.95. The firm has a market cap of $2.67 billion, a PE ratio of 3.82, a price-to-earnings-growth ratio of 0.95 and a beta of 0.60. Organon & Co. has a twelve month low of $8.01 and a twelve month high of $21.06.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, beating analysts' consensus estimates of $0.94 by $0.06. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.Organon & Co.'s revenue was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. Analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 11th. Stockholders of record on Friday, August 15th will be issued a $0.02 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.8%. Organon & Co.'s dividend payout ratio (DPR) is currently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.